Brief: Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept
23/02/2026 12:18
Feb 23 (Reuters) - Bristol-Myers Squibb Co BMY.N: BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOP-LINE RESULTS FROM REGISTRATIONAL PHASE 2 STUDY OF LUSPATERCEPT IN ADULTS WITH ALPHA (Α)-THALASSEMIA BRISTOL-MYERS SQUIBB CO - COHORTS MET PRIMARY AND SECONDARY ENDPOINTS BRISTOL-MYERS SQUIBB CO - REBLOZYL SHOWED SIGNIFICANT INCREASE IN HEMOGLOBIN LEVELS BRISTOL-MYERS SQUIBB CO - REBLOZYL SHOWED SIGNIFICANT DECREASE IN RBC TRANSFUSION BURDEN BRISTOL-MYERS SQUIBB CO - SAFETY FINDINGS CONSISTENT WITH KNOWN PROFILE OF REBLOZYL IN THALASSEMIA Source text: ID:nBwbFqRnta Further company coverage: BMY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bristol-Myers Squibb Co
See all newsFactbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Bristol Myers Squibb Announces Dividend
Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Izalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC